An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health
出版年份 2023 全文链接
标题
An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health
作者
关键词
-
出版物
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-28
DOI
10.1007/s12010-023-04748-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
- (2021) Baoyuan Zhang et al. Advanced Science
- KRAS G12C Mutations in NSCLC: From Target to Resistance
- (2021) Alfredo Addeo et al. Cancers
- Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
- (2020) Aaron C. Tan Thoracic Cancer
- Current therapy of KRAS-mutant lung cancer
- (2020) Aron Ghimessy et al. CANCER AND METASTASIS REVIEWS
- Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
- (2020) Qingyang Lei et al. Frontiers in Cell and Developmental Biology
- microRNA-1298 inhibits the malignant behaviors of breast cancer cells via targeting ADAM9
- (2020) Weili Chen et al. BIOSCIENCE REPORTS
- Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
- (2019) Jacqueline V. Aredo et al. LUNG CANCER
- FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
- (2019) Carlos J Diaz Osterman et al. eLife
- KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
- (2019) Emanuela Pupo et al. Frontiers in Oncology
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
- (2019) David E. Gerber et al. LUNG CANCER
- De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer
- (2018) Anju Singh et al. FASEB JOURNAL
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
- (2016) H. Kadara et al. ANNALS OF ONCOLOGY
- Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
- (2016) K.-J. Tang et al. CLINICAL CANCER RESEARCH
- FAK to the Rescue: Activated Stroma Promotes a “Safe Haven” for BRAF-Mutant Melanoma Cells by Inducing FAK Signaling
- (2015) Margaret C. Frame et al. CANCER CELL
- Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
- (2015) Matthias Scheffler et al. Oncotarget
- A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer
- (2014) N. Vasan et al. CLINICAL CANCER RESEARCH
- Heat shock protein 90 inhibitors in non-small-cell lung cancer
- (2014) Rathi N. Pillai et al. CURRENT OPINION IN ONCOLOGY
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non–Small-Cell Lung Cancer Segregated According to KRAS Mutation Status
- (2013) Giulio Metro et al. Clinical Lung Cancer
- The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance ofepidermal growth factor receptormutant lung cancer cells triggered by hepatocyte growth factor
- (2013) Takako Sano et al. INTERNATIONAL JOURNAL OF CANCER
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
- (2013) J Chen et al. Cell Death & Disease
- RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
- (2013) Georgia Konstantinidou et al. Cancer Discovery
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
- (2013) Ondrej Fiala et al. Cancer Genetics
- Association ofKRASandEGFRmutations with survival in patients with advanced lung adenocarcinomas
- (2012) Melissa L. Johnson et al. CANCER
- Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
- (2012) Paul K. Paik et al. CANCER
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- KRAS Mutations in Lung Cancer
- (2012) Niki Karachaliou et al. Clinical Lung Cancer
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
- (2012) Giulio Metro et al. LUNG CANCER
- Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy
- (2012) E. Giroux Leprieur et al. LUNG CANCER
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
- (2011) J. Yuan et al. MOLECULAR CANCER THERAPEUTICS
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis
- (2010) Michael Spoerner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
- (2010) Silvestre Vicent et al. JOURNAL OF CLINICAL INVESTIGATION
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling
- (2009) Yuliya Pylayeva et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
- (2009) Aristea Kalikaki et al. LUNG CANCER
- Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer
- (2009) R. Bao et al. MOLECULAR CANCER THERAPEUTICS
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk
- (2008) L. J. Chin et al. CANCER RESEARCH
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started